Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Botanical Drug Sponsors Would Benefit From Simpler Indications – FDAer

This article was originally published in The Tan Sheet

Executive Summary

Sponsoring botanical drug products with indications for less complex diseases - especially those that are currently without effective treatment - could speed up FDA's review of new botanical drugs, according to Shaw Chen, MD, PhD, Associate Director of CDER's Office of Drug Evaluation I
Advertisement

Related Content

FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency

Topics

Advertisement
UsernamePublicRestriction

Register

PS099644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel